Last reviewed · How we verify
Placebo: tablet of Rivaroxaban
Placebo: tablet of Rivaroxaban is a Factor Xa inhibitor Small molecule drug developed by Bayer. It is currently in Phase 3 development for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.
Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade.
Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade. Used for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Placebo: tablet of Rivaroxaban |
|---|---|
| Sponsor | Bayer |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by selectively inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots. This mechanism of action is specific to the coagulation pathway and does not affect other physiological processes.
Approved indications
- Deep vein thrombosis
- Pulmonary embolism
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Gastrointestinal bleeding
- Hemorrhage
- Anemia
- Thrombocytopenia
- Hypersensitivity reactions
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (PHASE3)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke (PHASE4)
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (PHASE4)
- Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism (PHASE4)
- ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty (PHASE3)
- Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo: tablet of Rivaroxaban CI brief — competitive landscape report
- Placebo: tablet of Rivaroxaban updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Placebo: tablet of Rivaroxaban
What is Placebo: tablet of Rivaroxaban?
How does Placebo: tablet of Rivaroxaban work?
What is Placebo: tablet of Rivaroxaban used for?
Who makes Placebo: tablet of Rivaroxaban?
What drug class is Placebo: tablet of Rivaroxaban in?
What development phase is Placebo: tablet of Rivaroxaban in?
What are the side effects of Placebo: tablet of Rivaroxaban?
What does Placebo: tablet of Rivaroxaban target?
Related
- Drug class: All Factor Xa inhibitor drugs
- Target: All drugs targeting Factor Xa
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Deep vein thrombosis
- Indication: Drugs for Pulmonary embolism
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Compare: Placebo: tablet of Rivaroxaban vs similar drugs
- Pricing: Placebo: tablet of Rivaroxaban cost, discount & access